10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Annual Report to Security Holders
Sublease Agreement with First Tracks Biotherapeutics Executed
Reg. FD
Change in Fiscal Year-End Approved by AnaptysBio Board
Announces First Quarter 2026 Financial Results and Provides Business Update
CFO Appointment - Christopher M. Murphy Named Chief Financial Officer
Amended material disclosure
Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
Q1
Amended Annual Report
FY 2025
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership